J Genet Med.  2022 Dec;19(2):43-48. 10.5734/JGM.2022.19.2.43.

Clinical application of prenatal chromosomal microarray

• Seol CA

• KMID: 2537685
• DOI: http://doi.org/10.5734/JGM.2022.19.2.43

Abstract

A prenatal chromosomal microarray (CMA) is generally recommended when a major anomaly is suspected on prenatal ultrasonography. As it can overcome the limitations of conventional karyotyping, it is expected that the number of prenatal CMA test requests will gradually increase. However, given the specificity of prenatal diagnosis, there are practical considerations compared to postnatal testing, such as the validation of prenatal specimens, maternal cell contamination, precautions when reporting variants of uncertain significance, and the need for comprehensive genetic counseling considering secondary findings. The purpose of this article is to provide necessary information to health care providers in consideration of these issues and to provide appropriate genetic counseling to patients.

Keyword

DNA Microarray; Prenatal diagnosis; Practice guideline; Genetic counseling